Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Perseus Proteomics Inc.. A complete text table follows the diagram.
Minimal direct cost leaves gross profit, but R&D and overhead overwhelm the small revenue base.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Cost of sales | 1 | 3.6M | 5.8% of reported total |
| Gross profit | 1 | 57.4M | 94.2% of reported total |
| Proteomics sales converted into gross profit | 2 | 61M | Reported six-month total · ¥61M |
| Operating loss | 2 | 400M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 461M | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Cost of sales | Proteomics sales converted into gross profit | 3.6M |
| Gross profit | Proteomics sales converted into gross profit | 57.4M |
| Proteomics sales converted into gross profit | Operating costs & expenses | 61M |
| Operating loss | Operating costs & expenses | 400M |